Aptevo rises after developing prostate cancer drug candidate with new technology

Aptevo Therapeutics

02/12/2020 17:16

** Drug developer's shares  APVO.O  rise 8.5% to $47.84
    ** Says it has developed a new drug candidate APVO442 for
treatment of prostate cancer using a new platform technology  urn:newsml:reuters.com:*:nACShHPfja
    ** Says new technology called ADAPTIR-FLEX enables the
design of candidates that have modified binding capacity to a
target which can improve tumor targeting and therapeutic benefit
    ** Prostate cancer is the most common type of cancer and the
second leading cause of cancer death among men in the United
States according to the National Cancer Institute
    ** Up to Tuesday's close, stock is up more than 381.3% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))